ArticleClinical and experimental medicine2026
Signal Transduction and Transcription Activator 1 in Pan-Cancer: Prognostic and Immunological Value.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STAT1, a key mediator of cellular responses to interferons and cytokines, has not been comprehensively analyzed in pan-cancer studies regarding its role in tumor biology. This study investigated STAT1 expression, its prognostic value, and its correlation with immune status in various types of cancer. We analyzed STAT1 expression, methylation, genomic alterations, survival, immune cell infiltration, and functional pathways using the TCGA, GTEx, GEO, TIMER, CCLE, and The Human Protein Atlas (HPA) databases. STAT1 expression was significantly higher in tumor tissues than in normal tissues and correlated with poorer overall survival. It was associated with the infiltration of B cells, CD4 + T cells, CD8 + T cells, neutrophils, macrophages, and dendritic cells. Enrichment analysis linked STAT1 to cancer-related pathways, cytokine-receptor interactions, and toll-like receptor signaling. Elevated STAT1 expression is associated with poor prognosis and immune infiltration, suggesting its potential as a biomarker and therapeutic target for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.